Market Place
Sourcing Support
Praxis Precision Medicines to Join April Conferences
03 Apr 2025 //
GLOBENEWSWIRE
Praxis Precision to Present Late-Stage Programs at AAN Meeting
24 Mar 2025 //
GLOBENEWSWIRE
Praxis To Participate In Five Upcoming Investor Conferences
04 Mar 2025 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Mar 2025 //
GLOBENEWSWIRE
Praxis moves ahead despite phase 3 tremor trial futility finding
28 Feb 2025 //
FIERCE BIOTECH
Praxis Provides Update On Essential3 & Corporate Strategy
28 Feb 2025 //
GLOBENEWSWIRE
Praxis Precision Announce Inducement Grants Under Nasdaq 5635(c)(4)
04 Feb 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at feb Investor Conferences
03 Feb 2025 //
GLOBENEWSWIRE
Praxis Highlights 2025 Corporate Strategy & Business Priorities
12 Jan 2025 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Praxis Precision Receives Rare Disease Designation for Relutrigine
18 Dec 2024 //
GLOBENEWSWIRE
Praxis Precision to Present at December Investor Conferences
03 Dec 2024 //
GLOBENEWSWIRE
Praxis to Showcase Update from Epilepsy Pipeline at AES 2024
26 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Q3 2024 Financials & Updates
06 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Attend 3 Nov Investor Conferences
06 Nov 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Report Q3 2024 Results on Nov 6
01 Nov 2024 //
GLOBENEWSWIRE
Praxis Presents On Ulixacaltamide At Movement Disorders Congress
26 Sep 2024 //
GLOBENEWSWIRE
Praxis To Participate In Upcoming Investor Conferences
05 Sep 2024 //
GLOBENEWSWIRE
Praxis To Present Epilepsy Portfolio At ILAE Congress
04 Sep 2024 //
GLOBENEWSWIRE
Praxis` Na+ channel blocker reduces seizures in 2 types of epilepsy in phase 2
03 Sep 2024 //
GLOBENEWSWIRE
Praxis To Announce Phase 2 EMBOLD Study Data For Relutrigine On Sept 3, 2024
02 Sep 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Q2 2024 Results And Corporate Update
13 Aug 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines To Report Q2 2024 Results On August 13
05 Aug 2024 //
GLOBENEWSWIRE
Praxis: Nasdaq Inducement Grants Announced
04 Jun 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
17 May 2024 //
GLOBENEWSWIRE
Praxis Provides Update, Reports Q1 2024 Financial Results
13 May 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Q1 2024 Results On May 13
10 May 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Nasdaq Listing Inducement Grants
03 May 2024 //
GLOBENEWSWIRE
Praxis At AAN On Ulixacaltamide
12 Apr 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines to Participate in Upcoming April Conferences
05 Apr 2024 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Apr 2024 //
GLOBENEWSWIRE
Praxis Precision Announces Pricing of $200 Million Public Offering
28 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
27 Mar 2024 //
GLOBENEWSWIRE
Praxis Positive Results of PRAX-628 Study Evaluating PPR Achieving 100% Response
26 Mar 2024 //
GLOBENEWSWIRE
Praxis’ epilepsy drug hits in phase 2, sparking stock rise
26 Mar 2024 //
FIERCE BIOTECH
Praxis Precision Medicines to Host PRAX-628 Program Update
25 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision Reports Fourth Quarter and Full-Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Praxis Precision to Participate in TD Cowen™s 44th Annual Health Care Conference
01 Mar 2024 //
GLOBENEWSWIRE
Praxis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02 Feb 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Pricing of $150.0 Million Public Offering
11 Jan 2024 //
GLOBENEWSWIRE
Praxis prices $150M public stock offering
11 Jan 2024 //
ENDPTS
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
10 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
08 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision Announces Collaboration Agreement with Tenacia
05 Jan 2024 //
GLOBENEWSWIRE
Praxis Precision to Showcase Largest Pipeline of Precision Epilepsy Programs
28 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines to Present at the Piper Sandler 35th Conference
21 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Receives PRIME Designation from EMA for elsunersen
16 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Third Quarter 2023 Financial Results
07 Nov 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
02 Oct 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines To Host Hybrid R&D Day on Monday, October 2, 2023
27 Sep 2023 //
GLOBENEWSWIRE
Praxis Precision to Present at H.C. Wainwright 25th Annual Investment Conference
07 Sep 2023 //
GLOBENEWSWIRE
Praxis Precision to Present Data from Epilepsy Portfolio at the 35th Congress
31 Aug 2023 //
GLOBENEWSWIRE
Praxis Precision to Present Analyses of Patient-Focused, Clinically Meaningful
28 Aug 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Reports Second Quarter 2023 Financial Results
09 Aug 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Positive Data from Study for Ulixacaltamide
08 Aug 2023 //
GLOBENEWSWIRE
Praxis Announces Positive Results of EEG Analysis of PRAX-628 Phase 1 Study
07 Aug 2023 //
GLOBENEWSWIRE
Praxis to Participate at the 2023 Wedbush PacGrow Healthcare Conference
03 Aug 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines Announces Closing of Financing &Reiterates Priorities
22 Jun 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
15 Jun 2023 //
GLOBENEWSWIRE
Praxis Precision Medicines, Inc. Announces Pricing of $59.1 M Public Offering
15 Jun 2023 //
GLOBENEWSWIRE
